Screening for Prostate Cancer: A Decision Analytic View

JAMA: The Journal of the American Medical Association

Volumn 272, Issue 10, 1994, Pages 773-780

  Krahn, Murray D ^a   Mahoney, John E ^a   Eckman, Mark H ^a   Trachtenberg, John ^a   Pauker, Stephen G ^a   Detsky, Allan S ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STAGING; HEALTH CARE COST; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; ULTRASOUND;

EID: 84942947587     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1994.03520100035030     Document Type: Article

References (83)

1. Lu-Yao GL, McLerran D, Wasson J, Wennberg JE. An assessment of radical prostatectomy: time trends, geographic variation, and outcomes. JAMA. 1993;269:2633-2636.
2. Boring CC, Squires TS, Tong T. Cancer statistics 1992. CA Cancer J Clin. 1992;42:19-38.
3. Optenberg SA, Thompson IM. Economics of screening for carcinoma of the prostate. Urol Clin North Am. 1990;17:719-737.
4. Kramer BS, Brown M, Prorok P, Potosky A, Gohagan J. Prostate cancer screening: what we know and what we need to know. Ann Intern Med. 1993;119:914-919.
5. Canadian Task Force on the Periodic Health Examination. Periodic health examination, 1991 update, 3: secondary prevention of prostate cancer. Can Med Assoc J. 1991;145:413-428.
6. Bowersox J. American Cancer Society adopts new cancer screening guidelines. J Natl Cancer Inst. 1992;84:1857.
7. Jewett HJ. The present status of radical prostatectomy for stages A and B prostatic cancer. J Urol. 1975;2:105-124.
8. Beck J, Pauker S. The Markov process in medical prognosis. Med Decis Making. 1983;3:419-458.
9. Mettlin C, Lee F, Drago J, Murphy GP. The American Cancer Society National Prostate Cancer Detection Project findings on the detection of early prostate cancer in 2425 men. Cancer. 1991; 67:2949-2958.
10. Labrie F, Dupont A, Suburu R, et al. Serum prostate-specific antigen as a prescreening test for prostate cancer. J Urol. 1992;147:846-852.
11. Catalona W, Smith D, Ratliff T, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324:1156-1161.
12. Mebane C, Gibbs T, Horm J. Current status of prostate cancer in North American black males. J Natl Med Assoc. 1990;82:782-788.
13. Spitz MR, Currier RD, Fueger JJ, Babaian RJ, Newell GR. Familial patterns of prostate cancer: a case-control analysis. J Urol. 1991;146:1305-1307.
14. Babaian RJ, Mettlin C, Kane R. The relationship of prostate-specific antigen to digital rectal examination and transrectal ultrasonography: findings of the American Cancer Society National Prostate Cancer Detection Project. Cancer. 1992;69:1195-1200.
15. Middleton RG, Snith JA, Melzer RB, Hamilton PE. Patient survival and local recurrence rate following radical prostatectomy for prostatic carcinoma. J Urol. 1986;136:422-424.
16. Fowler JE. Radical prostatectomy for stage A2 and B prostatic carcinoma. Urology. 1985;24:243-246.
17. Middleton AW. Radical prostatectomy for carcinoma in men more than 69 years old. J Urol. 1987;138:1185-1188.
18. Leandri P, Rossignol G, Gautier J, Ramon J. Radical retropubic prostatectomy: morbidity and quality of life: experience with 620 consecutive cases. J Urol. 1992;147:883-887.
19. Walsh PC, Lepor H. The role of radical prostatectomy in the management of prostatic cancer. Cancer. 1987;60:526-537.
20. Roos LL, Fisher ES, Sharp SM, Newhouse JP, Anderson G, Bubolz TA. Postsurgical mortality in Manitoba and New England. JAMA. 1990;263:2453-2458.
21. Igel TC, Barrett DM, Segura JW, Benson RC, Rife CC. Perioperative and postoperative complications from bilateral pelvic lymphadenectomy and radical retropubic prostatectomy. J Urol. 1987;137: 1189-1191.
22. Patterson DE, Zincke H. Perioperative complications of pelvic lymphadenectomy and radical retropubic prostatectomy in 150 patients. Urology. 1984;23:243-246.
23. Ritchie AWS, James K, De Kernion FB. Early postoperative morbidity of total prostatectomy. Br J Urology. 1989;64:511-515.
24. Roos NP, Ramsey EW. A population-based study of prostatectomy: outcomes associated with differing surgical outcomes. J Urol. 1987;137:1184-1187.
25. Wennberg JE, Roos NP, Sola L, Jaffe R. Use of claims data systems to evaluate health care outcomes. JAMA. 1987;257:933-936.
26. Lange PH, Reddy PK. Technical nuances and surgical results of radical retropubic prostatectomy in 150 patients. J Urol. 1987;138:348-352.
27. Walsh PC, Donker PJ. Impotence following radical prostatectomy: insight into etiology and prevention. J Urol. 1982;128:492-497.
28. Fowler FJ, Barry MJ, Lu-Yao G, Roman A, Wasson J, Wennberg JE. Patient-reported complications and follow-up treatment after radical prostatectomy. Urology. 1993;42:622-629.
29. Kinsey AC, Pomeroy WB, Martin CE. Age and sexual outlet. In: Kinsey AC, Pomeroy WB, Martin CE, eds. Sexual Behavior in the Human Male. Philadelphia, Pa: WB Saunders Co; 1948:218-262.
30. Steiner MS, Morton RA, Walsh PC. Impact of anatomical radical prostatectomy on urinary continence. J Urol. 1991;145:512-515.
31. Davies AH, Davis HL, Ramarakha P, Durrant KD, Fellows GJ. External beam radiation for carcinoma of the prostate. Euro Urol. 1990;18:117-119.
32. Bagshaw MA, Cox RC, Ramback JE. Radiation therapy for localized prostate cancer: justification by long-term follow-up. Urol Clin North Am. 1990; 17:787-802.
33. Hanks GE. Radiotherapy or surgery for prostate cancer? ten- and fifteen-year results of external beam therapy. Acta Oncol. 1991;30:231-237.
34. Schellhammer PF, el-Mahdi AM. Local failure and related complications after definitive treatment of carcinoma of the prostate by irradiation or surgery. Urol Clin North Am. 1990;17:835-851.
35. Pilepich MV. Radiation Therapy Oncology Group studies in carcinoma of the prostate. NCI Monogr. 1988;7:61-65.
36. Forman JD, Wharam MD, Lee DJ, Zinreich ES, Order SE. Definitive radiotherapy following prostatectomy: results and complications. Int J Radiat Oncol Biol Phys. 1986;12:185-189.
37. Pilepich MV, Perez CA, Walz BJ, Zivnuska FR. Complications of definitive radiotherapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1981;7:1341-1348.
38. Johansson J-E, Adami H-O, Andersson S-O, Bergstrom R, Holmberg L, Krusemo UB. High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA. 1992;267:2191-2196.
39. Zhang G, Wasserman NF, Sidi AA, Reinberg Y, Reddy PK. Long-term follow-up results after expectant management of stage Al prostatic cancer. J Urol. 1991;146:99-102.
40. Cantrell BB, De Klerk DP, Eggleston JC, Boitnott JK, Walsh PC. Pathological factors that influence prognosis in stage A prostatic cancer: the influence of extent versus grade. J Urol. 1981;125: 516-520.
41. Epstein JI, Paull G, Eggleston JC, Walsh PC. Prognosis of untreated stage Al prostatic carcinoma: a study of 94 cases with extended follow-up. J Urol. 1986;136:837-839.
42. Byar DP, Corle DK. VACURG randomized trial of radical prostatectomy for stages I and II prostatic cancer. Urology. 1981;17(suppl 4):7-11.
43. Lowe BA, Listrom MB. Management of stage A prostate cancer with a high probability of progression. J Urol. 1988;140:1345-1347.
44. Blute ML, Zincke H, Farrow GM. Long-term follow-up of young patients with stage A adenocarcinoma of the prostate. J Urol. 1986;136:840-843.
45. Adolffson J, Carstensen J. Natural course of clinically localized prostate adenocarcinoma in men less than 70 years old. J Urol. 1991;146:96-98.
46. Adolffson JA, Ronstrom L, Carstensen J, Lowhagen T, Hedlund PO. The natural course of low-grade, non-metastatic prostatic carcinoma. Br J Urol. 1990;65:611-614.
47. Whitmore WF, Warner JA, Thompson IM. Expectant management of localized prostatic cancer. Cancer. 1991;67:1091-1096.
48. Paulson DF, Moul JW, Walther PJ. Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocarcinoma: long-term results. J Urol. 1990;144:1180-1184.
49. Zincke H, Blute ML, Fallen MJ, Farrow GM. Radical prostatectomy for stage A adenocarcinoma of the prostate: staging errors and their implications for treatment recommendations and disease outcome. J Urol. 1991;146:1053-1058.
50. Blute ML, Nativ O, Zincke H, Farrow GM, Therneau T, Lieber MM. Pattern of failure after radical retropubic prostatectomy for clinically and pathologically localized adenocarcinoma of the prostate: influence of tumor deoxyribonucleic acid ploidy. J Urol. 1989;142:1262-1265.
51. Morton RA, Steiner MS, Walsh PC. Cancer control following anatomical radical prostatectomy: an interim report. J Urol. 1991;145:1197-1200.
52. Gibbons RP, Correa RJ, Brannen GE, Weissman RM. Total prostatectomy for clinically localized prostatic cancer: long-term results. J Urol. 1989;141:564-566.
53. Gibbons RP. Total prostatectomy for clinically localized prostate cancer: long-term surgical results and current morbidity. NCI Monogr. 1988;7: 123-126.
54. Gibbons R, Correa R, Brannen G, Mason J. Total prostatectomy for localized prostate cancer. J Urol. 1984;131:73-76.
55. Lepor H, Walsh P. Long-term results of radical prostatectomy in clinically localized prostate cancer: experience at the Johns Hopkins Hospital. NCI Monogr. 1988;7:117-122.
56. Lepor H, Kimball AW, Walsh PC. Cause-specific actuarial survival analysis: a useful method for reporting survival data in men with clinically localized carcinoma of the prostate. J Urol. 1989;141: 82-84.
57. Middleton RG, Larsen RH. Selection of patients with stage B prostate cancer for radical prostatectomy. Urol Clin North Am. 1990;17:779-785.
58. Chodak GW, Thisted RA, Gerber GS, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med. 1994;330: 242-248.
59. Cowen ME, Chartrand M, Weitzel WF. A Markov model of the natural history of prostate cancer. J Clin Epidemiol. 1994;47:3-21.
60. Fleming C, Wasson JH, Albertsen PC, Barry MJ, Wennberg JE, for the Prostate Patient Outcomes Research Team. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA. 1993;269:2650-2658.
61. Gonzalez EF, Eckman MH, Pauker SG. ‘Gambler': a computer workstation for patient utility assessment. In: Program and abstracts of the 14th annual meeting of the Society for Medical Decision Making; October 18, 1992; Portland, Ore. Abstract P-14.
62. Krahn M, Gafni A. Discounting in the evaluation of health care interventions. Med Care. 1993; 31:403-418.
63. Weinstein MC. Clinical Decision Analysis. Philadelphia, Pa: WB Saunders Co; 1980.
64. Laupacis A, Feeny D, Detsky A, Tugwell P. How attractive does a new technology have to be to warrant adoption and utilization? tentative guidelines for using clinical and economic evaluations. Can Med Assoc J. 1993;148:921-924.
65. Detsky AS, Naglie IG. A clinician's guide to cost-effectiveness analysis. Ann Intern Med. 1990; 113:147-154.
66. Labrie F, Dupont A, Suburu R, et al. Optimized strategy for detection of early stage, curable prostate cancer: role of prescreening with prostate-specific antigen. Clin Invest Med. 1993;16:425-439.
67. Burks DA, Littleton RH. The epidemiology of prostate cancer in black men. Henry Ford Hosp Med J. 1992;40:89-92.
68. Schuman LM, Mandel JS. Epidemiology of prostatic cancer in blacks. Prev Med. 1980;9:630-649.
69. Dayal HH, Chiu C. Factors associated with racial differences in survival for prostatic carcinoma. J Chronic Dis. 1982;35:553-560.
70. Fincham SM, Hill GB, Hanson J, Wijayasinghe C. Epidemiology of prostatic cancer: a case-control study. Prostate. 1990;17:189-206.
71. Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC. Family history and the risk of prostate cancer. Prostate. 1990;17:337-347.
72. Dorr VJ, Williamson SK, Stephens RL. An evaluation of prostate-specific antigen as a screening test for prostate cancer. Arch Intern Med. 1993; 153:2529-2537.
73. Walsh PC. Why make an early diagnosis of prostate cancer? J Urol. 1992;147:853.
74. US Preventive Services Task Force. Guide to Clinical Preventive Services: An Assessment of the Effectiveness of 169 Interventions. Baltimore, Md: Williams & Wilkins; 1989:63.
75. Lawrence RS, for the US Preventive Services Task Force. Screening for Prostate Cancer: A Commentary on the Canadian Task Force on the Periodic Health Examination: 1991 Update on the Secondary Prevention of Prostate Cancer. Washington, DC: US Preventive Services Task Force; 1992:1-23.
76. Green CJ, Hadorn D, Bassett K, Kazanjian A. Prostate-Specific Antigen in the Early Detection of Prostate Cancer. Vancouver, British Columbia: British Columbia Of Fice of Health Technology Assessment; 1993.
77. Miller AB. Screening for cancer: state of the art and prospects for the future. World J Surg. 1989; 13:79-83.
78. Singer PA, Tasch ES, Stocking C, Rubin S, Siegler M, Weichselbaum W. Sex or survival: tradeoffs between quality and quantity of life. J Clin Oncol. 1991;9:328-334.
79. Steineck G, Adolffson J, Whitmore WF. Local recurrence and disease-free survival: doubtful parameters when comparing nonrandomized studies of prostate cancer. Scand J Urol Nephrol Suppl. 1991;138:121-126.
80. Newling D. What is 'progression' in prostate cancer. Prostate. 1992;19(suppl 4):139-142.
81. Catalona W, Smith D, Ratliff T, Basler J. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA. 1993;270:948-954.
82. Eddy DM. Finding cancer in asymptomatic people: estimating the benefits, costs, and risks. Cancer. 1983;51:2440-2445.
83. Black WC, Welch HG. Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N Engl J Med. 1993; 328:1237-1243.